Literature DB >> 2462442

Bradykinin induced wheal and flare is not mediated by histamine release or cyclooxygenase products.

D C Crossman1, R W Fuller.   

Abstract

The wheal and flare response to intradermal bradykinin was studied in man. The possibility that histamine and cyclooxygenase products are involved in the response to bradykinin was examined. Terfenadine given by mouth significantly inhibited the cutaneous response to histamine but the effect of bradykinin was unaltered. Similarly the cutaneous response to bradykinin was unchanged by aspirin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462442      PMCID: PMC1386511          DOI: 10.1111/j.1365-2125.1988.tb03375.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Histamine is released from skin by substance P but does not act as the final vasodilator in the axon reflex.

Authors:  P J Barnes; M J Brown; C T Dollery; R W Fuller; D J Heavey; P W Ind
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

2.  Role of prostaglandin-mediated vasodilatation in inflammation.

Authors:  T J Williams; M J Peck
Journal:  Nature       Date:  1977-12-08       Impact factor: 49.962

3.  Effect of enalapril on the skin response to bradykinin in man.

Authors:  R W Fuller; J B Warren; M McCusker; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

4.  Prostaglandin E2, prostaglandin I2 and the vascular changes of inflammation.

Authors:  T J Williams
Journal:  Br J Pharmacol       Date:  1979-03       Impact factor: 8.739

5.  Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man.

Authors:  D J Heavey; S E Barrow; N E Hickling; J M Ritter
Journal:  Nature       Date:  1985 Nov 14-20       Impact factor: 49.962

6.  Bradykinin-induced bronchoconstriction in humans. Mode of action.

Authors:  R W Fuller; C M Dixon; F M Cuss; P J Barnes
Journal:  Am Rev Respir Dis       Date:  1987-01

7.  Sensory neuropeptide effects in human skin.

Authors:  R W Fuller; T B Conradson; C M Dixon; D C Crossman; P J Barnes
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

  7 in total
  8 in total

1.  The effect of sulindac on dermal responses to bradykinin in normal subjects given an angiotensin converting enzyme inhibitor.

Authors:  R E Ferner; F Kamali; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

2.  The importance of bradykinin and histamine in the skin response to antigen.

Authors:  J B Warren; C M Newman; F J Pixley; R W Fuller; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

3.  The effect of indomethacin and enalapril on the cutaneous response to bradykinin.

Authors:  L G McAlpine; N C Thomson
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

4.  Effect of enalapril on allergen-induced cutaneous hypersensitivity reaction.

Authors:  J R Snyman; D K Sommers
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

5.  Cutaneous blood flow changes and weal induced by intradermal bradykinin following pretreatment with indomethacin and captopril.

Authors:  T C Wa; E D Cooke; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Acute effect of inhaled bradykinin on tracheobronchial clearance in normal humans.

Authors:  R Polosa; A Hasani; D Pavia; J E Agnew; C K Lai; S W Clarke; S T Holgate
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

7.  Comparative nasal effects of bradykinin, kallidin and [Des-Arg9]-bradykinin in atopic rhinitic and normal volunteers.

Authors:  K Rajakulasingam; R Polosa; S T Holgate; P H Howarth
Journal:  J Physiol       Date:  1991-06       Impact factor: 5.182

8.  Characterisation and mechanisms of bradykinin-evoked pain in man using iontophoresis.

Authors:  Kathryn J Paterson; Laura Zambreanu; David L H Bennett; Stephen B McMahon
Journal:  Pain       Date:  2013-01-11       Impact factor: 6.961

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.